Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Abiomed Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Abiomed Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Net income (loss)
Depreciation and amortization
Acquired in-process research & development
Bad debt expense (recoveries)
Stock-based compensation
Write-down of inventory and other
Accretion on marketable securities
Change in fair value of other investments
Gain on previously held interest in preCARDIA
Excess tax benefit from stock-based awards
Deferred tax provision
Change in fair value of contingent consideration
Other non-cash operating activities
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities
Deferred revenue
Changes in assets and liabilities
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Net cash provided by operating activities
Purchases of marketable securities
Proceeds from the sale and maturity of marketable securities and other
Purchases of other investments
Acquisition of preCARDIA, net of cash acquired
Acquisition of Breethe, net of cash acquired
Proceeds from sale of Shockwave Medical securities
Purchases of property and equipment
Net cash (used for) provided by investing activities
Proceeds from the exercise of stock options
Excess tax benefit from stock-based awards
Taxes paid related to net share settlement upon vesting of stock awards
Payment of Breethe contingent consideration at acquisition date fair value
Repurchase of common stock
Proceeds from the issuance of stock under employee stock purchase plan
Principal payments on capital lease obligation
Net cash provided by (used for) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).

Net income (loss)
The net income fluctuates considerably across quarters, with significant increases noted around mid-2018 and early 2019, reaching highs above $90 million. However, there are fluctuations with some quarters showing reduced profitability or losses, notably in the first quarter of 2021 and in late 2019. The trend from late 2020 through 2022 shows recovery and growth, culminating in a peak of $106 million in September 2022.
Depreciation and amortization
This expense generally escalates over time, beginning at around $1.4 million and steadily rising to approximately $6.7 million by late 2022, suggesting increased investments in fixed assets or capitalized intangible assets.
Stock-based compensation
Stock-based compensation expenses show variability but generally trend upward, with intermittent spikes. A notably low value appeared in the first quarter of 2020; however, the overall pattern suggests increasing costs related to equity incentives, reaching around $16 million in late 2022.
Write-down of inventory and other
This item shows irregular but rising values, with a significant peak in the third quarter of 2022 surpassing $9 million. Earlier quarters show moderate to high inventory write-downs, indicating periodic adjustments and potential challenges in inventory management or valuation.
Bad debt expense (recoveries)
Bad debt expense is relatively minimal throughout, with small positive and negative fluctuations, indicating occasional recoveries or minor expenses related to receivables.
Deferred tax provision
This item is highly volatile, with substantial fluctuations between positive and negative values. Notable positive spikes occur intermittently, whereas large negative spikes may reflect tax planning or adjustments affecting tax liabilities.
Change in fair value of other investments
From 2018 onwards, significant fluctuations are observed with extreme negative and positive values alternating, indicating marked volatility in investment valuation that impacts the financial results significantly.
Acquisition-related items
There are large one-time acquisitions reflected in late 2020 and early 2021, with significant cash outflows for acquisitions such as preCARDIA and Breethe. These acquisitions correspond with large contingent consideration changes and fair value adjustments affecting the financial statements.
Operating assets and liabilities
Changes in accounts receivable, inventories, and other working capital components exhibit significant volatility, with episodes of both increases and decreases suggesting fluctuations in collection cycles, inventory management, and prepaid expenses. Particularly, accounts receivable and inventories show large negative movements in some quarters, indicating potential pressure on working capital.
Net cash provided by operating activities
Operating cash flow remains generally strong, with consistent positive cash generation in most quarters. Peaks occur in late 2019 and mid-2021, though some quarters demonstrate lower inflows, possibly due to working capital fluctuations or net income variability.
Investing activities
Investing cash flow is predominantly negative, indicative of ongoing investments in marketable securities, property, and equipment, as well as acquisitions. Occasional positive cash inflows from sales or maturities of marketable securities partially offset these outflows. Some quarters experience extremely large outflows, especially during acquisition periods.
Financing activities
Financing cash flows are inconsistent, with both inflows from stock option exercises and employee stock purchase plans, and significant outflows related to repurchases of common stock, payment of contingent considerations, and taxes related to stock settlements. Large repurchase programs are evident in late 2018 and continuing sporadically through 2022. The overall pattern reflects active capital management and shareholder return strategies.
Cash and cash equivalents changes
Quarterly net changes in cash demonstrate variability, with some quarters showing substantial increases while others experience sizeable reductions. The fluctuations correspond closely with the interplay of operating cash generation, investing outflows for acquisitions and capital expenditures, and financing activities, including stock repurchases and issuance.